Sarepta's Elevidys shows benefit in older Duchenne patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Sarepta's Elevidys shows benefit in older Duchenne patients

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Olde

September 30, 2026 8:30 AM EDT

Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to a well-matched external control group Separate findings in children treated at ages 2 to under 3 demonstrated robust delandistrogene moxeparvovec-dystrophin expression and transduction efficiency at 12 weeks In these analyses, the safety profile of delandistrogene moxeparvovec remained consistent and no new signals were identified

CAMBRIDGE, Mass.--(BUSINESS... More